title: EBV DNA: a Hodgkin lymphoma biomarker?
abstract: In this issue of Blood, Kanakry and colleagues report that increased pretreatment levels of plasma Epstein Barr virus DNA (EBV-DNA), as determined by quantitative real-time polymerase chain reaction (QRT-PCR), are associated with inferior outcomes among patients with previously untreated, advanced-stage Hodgkin lymphoma.
authors: Queen's University, Canada.
authors: Ralph M
authors: RM
authors: Meyer
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004279:DNA, Viral / Q000097:blood*; D020031:Epstein-Barr Virus Infections / Q000175:diagnosis*; D005260:Female; D004854:Herpesvirus 4, Human / Q000235:genetics*; D006689:Hodgkin Disease / Q000175:diagnosis* / Q000188:drug therapy*; D006801:Humans; D008297:Male
chemical_list: D004279:DNA, Viral